Measuring cognition and function in the preclinical stage of Alzheimer's disease

Sandra Weintraub; Maria C. Carrillo; Sarah Tomaszewski Farias; Terry E. Goldberg; James A. Hendrix; Judith Jaeger; David S. Knopman; Jessica B. Langbaum; Denise C. Park; Michael T. Ropacki; Sietske A.M. Sikkes; Kathleen A. Welsh-Bohmer; Lisa J. Bain; Robert Brashear; Kumar Budur; Ana Graf; Ferenc Martenyi; Marta Segardahl Storck; Christopher Randolph

doi:10.1016/j.trci.2018.01.003

Measuring cognition and function in the preclinical stage of Alzheimer's disease

Sandra Weintraub
, Maria C. Carrillo
, Sarah Tomaszewski Farias
, Terry E. Goldberg
, James A. Hendrix^*
, Judith Jaeger
, David S. Knopman
, Jessica B. Langbaum
, Denise C. Park
, Michael T. Ropacki
, Sietske A.M. Sikkes
, Kathleen A. Welsh-Bohmer
, Lisa J. Bain
, Robert Brashear
, Kumar Budur
, Ana Graf
, Ferenc Martenyi
, Marta Segardahl Storck
, Christopher Randolph

^*Corresponding author for this work

Clinical Neuropsychology

Research output: Contribution to Journal › Short survey › Academic › peer-review

Abstract

The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.

Original language	English
Pages (from-to)	64-75
Number of pages	12
Journal	Alzheimer's and Dementia: Translational Research and Clinical Interventions
Volume	4
DOIs	https://doi.org/10.1016/j.trci.2018.01.003
Publication status	Published - 1 Jan 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.trci.2018.01.003

Persistent URL (handle)

Persistent link

Cite this

Weintraub, S., Carrillo, M. C., Farias, S. T., Goldberg, T. E., Hendrix, J. A., Jaeger, J., Knopman, D. S., Langbaum, J. B., Park, D. C., Ropacki, M. T., Sikkes, S. A. M., Welsh-Bohmer, K. A., Bain, L. J., Brashear, R., Budur, K., Graf, A., Martenyi, F., Storck, M. S., & Randolph, C. (2018). Measuring cognition and function in the preclinical stage of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 4, 64-75. https://doi.org/10.1016/j.trci.2018.01.003

@article{d35531d47d084c9abde256f8ff2f578e,

title = "Measuring cognition and function in the preclinical stage of Alzheimer's disease",

abstract = "The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.",

author = "Sandra Weintraub and Carrillo, \{Maria C.\} and Farias, \{Sarah Tomaszewski\} and Goldberg, \{Terry E.\} and Hendrix, \{James A.\} and Judith Jaeger and Knopman, \{David S.\} and Langbaum, \{Jessica B.\} and Park, \{Denise C.\} and Ropacki, \{Michael T.\} and Sikkes, \{Sietske A.M.\} and Welsh-Bohmer, \{Kathleen A.\} and Bain, \{Lisa J.\} and Robert Brashear and Kumar Budur and Ana Graf and Ferenc Martenyi and Storck, \{Marta Segardahl\} and Christopher Randolph",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/j.trci.2018.01.003",

language = "English",

volume = "4",

pages = "64--75",

journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",

issn = "2352-8737",

publisher = "John Wiley and Sons Inc.",

}

Weintraub, S, Carrillo, MC, Farias, ST, Goldberg, TE, Hendrix, JA, Jaeger, J, Knopman, DS, Langbaum, JB, Park, DC, Ropacki, MT, Sikkes, SAM, Welsh-Bohmer, KA, Bain, LJ, Brashear, R, Budur, K, Graf, A, Martenyi, F, Storck, MS & Randolph, C 2018, 'Measuring cognition and function in the preclinical stage of Alzheimer's disease', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 4, pp. 64-75. https://doi.org/10.1016/j.trci.2018.01.003

TY - JOUR

T1 - Measuring cognition and function in the preclinical stage of Alzheimer's disease

AU - Weintraub, Sandra

AU - Carrillo, Maria C.

AU - Farias, Sarah Tomaszewski

AU - Goldberg, Terry E.

AU - Hendrix, James A.

AU - Jaeger, Judith

AU - Knopman, David S.

AU - Langbaum, Jessica B.

AU - Park, Denise C.

AU - Ropacki, Michael T.

AU - Sikkes, Sietske A.M.

AU - Welsh-Bohmer, Kathleen A.

AU - Bain, Lisa J.

AU - Brashear, Robert

AU - Budur, Kumar

AU - Graf, Ana

AU - Martenyi, Ferenc

AU - Storck, Marta Segardahl

AU - Randolph, Christopher

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.

AB - The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.

UR - https://www.scopus.com/pages/publications/85042848973

UR - https://www.scopus.com/pages/publications/85042848973#tab=citedBy

U2 - 10.1016/j.trci.2018.01.003

DO - 10.1016/j.trci.2018.01.003

M3 - Short survey

AN - SCOPUS:85042848973

SN - 2352-8737

VL - 4

SP - 64

EP - 75

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

ER -

Measuring cognition and function in the preclinical stage of Alzheimer's disease

Abstract

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this